Stockreport

BioAtla and GATC Health to advance Oz-V in Phase III trial [Yahoo! Finance]

BioAtla, Inc.  (BCAB) 
PDF trial for second-line and later (2L+) oropharyngeal squamous cell carcinoma (OPSCC). As part of transaction, BioAtla is set to receive an initial $5m from Inversagen A [Read more]